Trial Profile

An Open-Label, Multiple-Center, Phase I/II Dose Escalation Study for the Safety and Efficacy of NGGT002 in Adults With Classic Phenylketonuria

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NGGT 002 (Primary)
Indications Phenylketonuria
Focus Adverse reactions; Therapeutic Use
Sponsors Next Generation Gene Therapeutics

Most Recent Events

10 Dec 2024 Planned initiation date changed from 22 Nov 2024 to 10 Jan 2025.
11 Nov 2024 According to the Next Generation Gene Therapeutics Media Release, first patients in trial will be dosed based on the effective dose which has been proved in the IIT study. And company is enthusiastic about the upcoming results from this trial.
02 Oct 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com